Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Will be Virtual Boston USA March 6-10, 2021 Back

Tweet

New PrEP at CROI 2021       CROI: NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS - (03/08/21)   CROI: ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP - (03/08/21)   CROI: Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI - (03/10/21)   CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH - (03/09/21)   CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR - (03/09/21)   CROI: LONG-ACTING HIV CAPSID INHIBITOR EFFECTIVE AS PrEP IN A SHIV RHESUS MACAQUE MODEL - (03/06/21)